|

Tinengotinib at the optimal dose combined with Fulvestrant Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • TransThera Sciences (Nanjing), Inc.1

Indications

  • Breast Cancer1
  • Cancer1

Other1 trial

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.